Emerging Growth Research Reiterates Buy-Extended Rating on SBC Medical Group

Research firm maintains $9.00 price target following Q4:25 quarterly update for healthcare services company.

Apr. 7, 2026 at 7:23am

Got story updates? Submit your updates here. ›

A high-contrast black-and-white macro photograph of complex medical machinery, conveying a sense of institutional power and financial security within the healthcare industry.Emerging research highlights SBC Medical Group's technological capabilities and financial strength as it navigates industry changes.NYC Today

Emerging Growth Research has released its latest quarterly update on SBC Medical Group Holdings, Inc., reiterating a Buy-Extended rating and $9.00 price target for the company's stock. The report highlights SBC's Q4:25 financial results, ongoing business transition, and outlook for a return to revenue growth in 2026 following pricing-related headwinds in 2025.

Why it matters

SBC Medical Group is a major provider of management services to cosmetic treatment centers through a franchise model, operating across dermatology, aesthetics, and other healthcare verticals primarily in Japan and Southeast Asia. The company's performance and strategic positioning are closely watched by investors and industry analysts as indicators of broader trends in the medical services and aesthetics sectors.

The details

Key points from Emerging Growth Research's quarterly update include SBC's Q4:25 revenue decline due to franchise fee changes, improved profitability, a strong cash position, continued underlying volume growth, and the company's focus on operational efficiency and long-term growth initiatives like international expansion and new AI-driven offerings. The report notes SBC's shares remain discounted compared to historical performance and internal valuation frameworks, with expectations for a gradual revenue recovery in 2026.

  • SBC reported Q4:25 financial results in early April 2026.
  • Emerging Growth Research released its quarterly update on April 6, 2026.
  • The report maintains a 12-month price target through April 2027.

The players

SBC Medical Group Holdings, Inc.

A provider of management services to cosmetic treatment centers through a franchise model, operating primarily in Japan and Southeast Asia with expanding U.S. operations.

Emerging Growth Research

An independent equity research firm that covers emerging and growth-oriented public companies.

Got photos? Submit your photos here. ›

What’s next

Emerging Growth Research will continue to monitor SBC Medical Group's performance and provide updates to investors on the company's progress in executing its growth strategy and returning to revenue growth in 2026.

The takeaway

Despite facing some short-term pricing headwinds, SBC Medical Group remains a well-capitalized leader in the medical aesthetics franchise space, with a focus on operational efficiency and long-term international expansion that positions the company for a potential return to stronger growth in the coming years.